PRNewsWire
19 Dec 2025, 12:44 UTC · 46w ago
Impact · against what's priced in
GTBP provides tangible de-risking as its lead candidate enters the predicted efficacy range without dose-limiting toxicities and moves toward solid tumor trials. For the larger immunotherapy players, the news is largely thematic and reflects general sector growth already recognized by the market.
No priced-in read yet
What the story claims
4 claims · scored −1 bearish … +1 bullish
The CAR-T cell therapy market is projected to grow from $3.87 billion in 2024 to $13.25 billion by 2030.
More positive than 93% of claims this week
GT Biopharma's Phase 1 trial of GTB-3650 has advanced to Cohort 4, reaching a dose level where clinical efficacy is predicted to begin.
Continue reading
5 related stories
The company has advanced GTB-3650 to Cohort 4 (10μg/kg/day), reaching the dose level where clinical efficacy is predicted to begin without dose-limiting toxicities.
Read from the article alone
No priced-in read yet
Positioned as a beneficiary of a CAR-T cell therapy market projected to grow to $13.25 billion by 2030.
Read from the article alone
No priced-in read yet
Benefits from the general shift toward immunotherapies and the recent FDA approval of the first bispecific antibody combination for second-line blood cancer.
Read from the article alone
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
More positive than 76% of claims this week
GT Biopharma expects to submit regulatory filings to begin human trials for its solid tumor candidate, GTB-5550, in late December 2025 or January 2026.
So whatExpanding from blood cancers into solid tumors significantly increases the potential patient population and valuation of the pipeline.
More positive than 62% of claims this week
The FDA approved the first bispecific antibody combination for second-line blood cancer treatment in November.
So whatValidates the regulatory pathway for the technology class, benefiting multiple firms in the space including REGN and GMAB.
More positive than 49% of claims this week
Which stocks this story touches
More positive than 87% of ticker scores this week
The company is advancing its Phase 1 clinical trial to Cohort 4 with no dose-limiting toxicities and preparing for new human trials for GTB-5550.
More positive than 65% of ticker scores this week
Positioned as a beneficiary of the transformative power of immunotherapy in the growing blood cancer market.
More positive than 65% of ticker scores this week
Positioned as a beneficiary of the transformative power of immunotherapy in the growing blood cancer market.
More positive than 65% of ticker scores this week
Positioned as a beneficiary of the transformative power of immunotherapy in the growing blood cancer market.
More positive than 65% of ticker scores this week
Positioned as a beneficiary of the transformative power of immunotherapy in the growing blood cancer market.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
PRNewsWire
6h ago
More positive than 36% of relationship scores this week
[mutual] Both companies are positioned in the immunotherapy and blood cancer treatment market.
More positive than 36% of relationship scores this week
[mutual] Both companies are positioned in the immunotherapy and blood cancer treatment market.
More positive than 36% of relationship scores this week
[mutual] Both companies are positioned in the immunotherapy and blood cancer treatment market.
More positive than 36% of relationship scores this week
[mutual] Both companies are positioned in the immunotherapy and blood cancer treatment market.
More positive than 36% of relationship scores this week
[mutual] Both companies are positioned in the immunotherapy and blood cancer treatment market.
More positive than 36% of relationship scores this week
[mutual] Both companies are positioned in the immunotherapy and blood cancer treatment market.
More positive than 36% of relationship scores this week
[mutual] Both companies are positioned in the immunotherapy and blood cancer treatment market.
More positive than 36% of relationship scores this week
[mutual] Both companies are positioned in the immunotherapy and blood cancer treatment market.
More positive than 36% of relationship scores this week
[mutual] Both companies are positioned in the immunotherapy and blood cancer treatment market.
−77.0%
Price is moving against the score
$4.23 vs $18.37 close before publication (Dec 18) · not market-adjusted
GTBP chart →+71.1%
Price agrees with the score
$53.89 vs $31.50 close before publication (Dec 18) · not market-adjusted
GMAB chart →−15.9%
Price is moving against the score
$1.32 vs $1.57 close before publication (Dec 18) · not market-adjusted
AUTL chart →
